DEA

DEA Rules THCA Is Not Legal Hemp Amid Industry Shake-Up And Farm Bill Debate On Delta-8 THC Prohibition
GOP Senator Presses Antony Blinken On Illicit Cannabis Operations Linked To Chinese Organized Crime Groups, Sec Of State Defers To DEA
EXCLUSIVE: Cannabis Researcher On Marijuana Rescheduling — 'Removing Barriers' Will Help, But 'Knowledge Gap' Is Huge
GOP Senator Presses Antony Blinken On Illicit Cannabis Operations Linked To Chinese Organized Crime Groups, Sec Of State Defers To DEA
EXCLUSIVE: Cannabis Researcher On Marijuana Rescheduling — 'Removing Barriers' Will Help, But 'Knowledge Gap' Is Huge
GOP Senator Says Biden's Campaign Strategy Is To Get More People To 'Smoke Marijuana' And He's Not Joking
EXCLUSIVE: We Analyzed 4,000+ DEA Marijuana Rescheduling Comments; Here's What Americans Really Think

DEA Recent News

DEA Vs. Dept Of Justice Over Cannabis Rescheduling: Too Many Cooks In The Kitchen?
Current and former DEA agents say they need 'more time' and scientific evidence. But the HHS recommended reclassifying cannabis in 2023.
Cannabis Stocks Rallied After Rescheduling News, Investment Management Firm Co-Founder Discusses Impact And Next Steps
Explore how DOJ's cannabis rescheduling boosts stocks and insights from Emily Paxhia on the industry's future. Read now!
[Infographic] DEA's Proposed Rules For Marijuana: What You Need To Know
The Dept. of Justice (DOJ) proposes rescheduling marijuana to Schedule III under the Controlled Substances Act.
Cannabis Rescheduling: When Will It Happen? Expert Lays Out Timeline, Risks And Wild Cards
The Department of Justice (DOJ) confirmed that it has started the formal rulemaking process to reclassify cannabis to Schedule III. This significant step reinforces the positive outlook for cannabis stocks.
Attorney General Merrick Garland Initiates Process To Reschedule Cannabis With DOJ Legal Review, Where's The DEA?
AG Merrick Garland formally initiated the rescheduling process that includes a 60-day public comment period.
Freedom's Just Another Word For Losing 2,000 Cannabis Plants In Maine Police Raid
Freedom is a rural town in Central Maine (pop. 697) where authorities seized weed plants after an investigation discovered the operation.
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Armed Robbers Make Off With $437,000 From Marijuana Courier: Cannabis Banking Reform Would Stem Cannabis Dispensary Attacks Where Workers Are Sitting Ducks
Retail weed shops are forced to be cash-only, and violent attacks on workers have increased across the country.
Anti-Cannabis Group Raises Money To Scuttle DEA Rescheduling Effort
Almost immediately following the DEA's announcement, "Smart Approaches to Marijuana" (SAM) began soliciting donations to oppose this change.
DEA And Cannabis Rescheduling: A Rollercoaster Ride You Don't Want To Miss, But Keep Your Seatbelts On
DEA's decision not to sign the rescheduling order caused a roller coaster ride for the cannabis industry, with more confusion ahead.
Post Cannabis Rescheduling: What's Next For Marijuana Giants? Potential $1.1B Cash Flow Boost From IRS 280E Removal
Following the recent move on the part of the DEA toward 
Criminal Defense Lawyers To Biden: Release Pot Prisoners As DEA Moves To Reclassify Cannabis
There are approximately 22,000 pot prisoners serving time in state correctional facilities and around 10,000 in federal prisons. Biden can only pardon those in federal prisons.
GOP Senator Bashes Dems' Push For Marijuana Legalization As Pro-Criminal & Anti-American: 'It's Obscene'
GOP Senator Bill Hagerty accused the Democrats of pursuing policies that are pro-criminal and anti-American.
Is Cannabis Rescheduling Imminent?
Rumors of an imminent drug policy announcement swept through the industry Tuesday morning after the Associated Press reported the Drug Enforcement Administration (DEA) plans to reschedule cannabis.
Billions On The Move: Tracking Market Cap Changes In Top Cannabis Firms After DEA Rescheduling Announcement
Tuesday's announcement that the DEA is moving towards rescheduling cannabis from Schedule I to Schedule III, has already injected billions into the publicly traded market for cannabis companies.
DEA Moves To Reschedule Weed, Cannabis Stocks Go For Wild Ride, Pummel Short Sellers With $210M In Losses
Cannabis stocks soared following Tuesday's news that the DEA intends to designate marijuana from Schedule I to Schedule III.
Cannabis Advocates Say DEA's Move Represents 'Progress But Not Justice,' Ends War On Medical Marijuana Patients, But Not War On Drugs
Cannabis Stocks React To DEA Rescheduling: Canopy & Aurora Surge, Tilray, WM Tech Hold Steady
In a historic trading session on Tuesday, cannabis stocks soared following the DEA's reported decision to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act.
Rep Blumenauer On Marijuana Reclassification: 'Legalization Is Inevitable, Biden-Harris Admin Is Listening' To The People
In a landmark decision that could reshape the landscape of American drug policy, the U.S.
DEA's Move To Reclassify Cannabis Seen As 'Significant,' But Fails To Resolve State-Federal Conflict
DEA calls for reclassification of botanical cannabis from Schedule I to III under federal law. NORML praises decision but cautions on state/federal divide.
Cannabis Stocks And ETFs Surge As DEA Moves To Reschedule Marijuana
The cannabis sector saw a notable upswing on Tuesday on news of the Drug Enforcement Administration's (DEA) historic decision to align its stance with a recommendation from the Department of Health and Human Services and move
US Cannabis Council Calls DEA Historic Decision To Reclassify Cannabis 'A Tectonic Shift'
Conklin emphasized the importance of this decision, stating, "The US Cannabis Council strongly supports the move by the DEA"
Breaking: DEA Reportedly Moves To Reschedule Cannabis, Stocks Rise Sharply On The News
The DEA plans to reclassify marijuana as a less dangerous drug with medical uses, a historic shift that could have ripple effects across the US.